Blog
About

  • Record: found
  • Abstract: found
  • Article: not found

Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: a pooled analysis.

Read this article at

ScienceOpenPublisherPubMed
Bookmark
      There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

      Abstract

      There is a paucity of evidence for outcome predictors in patients with major depressive disorder (MDD) not responding to initial antidepressant therapy (ADT). This post-hoc analysis evaluated whether MDD severity affects response to adjunctive aripiprazole.

      Related collections

      Author and article information

      Affiliations
      [1 ] Yale School of Medicine, New Haven, CT, USA.
      [2 ] Otsuka America Pharmaceutical, Inc., Princeton, NJ, USA.
      [3 ] Otsuka Pharmaceutical Development and Commercialization, Princeton, NJ, USA.
      [4 ] Bristol-Myers Squibb, Plainsboro, NJ, USA.
      [5 ] Bristol-Myers Squibb, Wallingford, CT, USA.
      [6 ] Yale School of Medicine, New Haven, CT, USA; Bristol-Myers Squibb, Wallingford, CT, USA.
      [7 ] Department of Psychiatry, University of California, San Francisco, 401 Parnassus Avenue, San Francisco, CA 94143, USA. Electronic address: CraigN@lppi.ucsf.edu.
      Journal
      J Affect Disord
      Journal of affective disorders
      1573-2517
      0165-0327
      Jun 2014
      : 162
      24766999 S0165-0327(14)00119-0 10.1016/j.jad.2014.03.017
      Copyright © 2014. Published by Elsevier B.V.

      Comments

      Comment on this article